{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:24:05Z","timestamp":1788967445403,"version":"build-2803163510"},"reference-count":14,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2014,4,30]],"date-time":"2014-04-30T00:00:00Z","timestamp":1398816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics and Practice"],"abstract":"<jats:p>A 55-year old man was treated with sunitinib 50 mg\/day for 4 weeks on and 2 weeks off, as a first-line therapy for metastatic renal cell carcinoma. During the fourth week of the first cycle, he was admitted to the Emergency Department with abdominal pain and vomiting. Acute acalculous cholecystitis was diagnosed. Sunitnib-associated cholecystitis is a rare adverse event previously reported in few cases. The mechanism behind this complication is not fully understood, although vascular endothelial dysfunction may play a role. The use of this drug is expanding in clinical oncology, and physicians should be aware of this life-threating adverse event.<\/jats:p>","DOI":"10.4081\/cp.2014.635","type":"journal-article","created":{"date-parts":[[2014,4,30]],"date-time":"2014-04-30T12:42:09Z","timestamp":1398861729000},"page":"635","source":"Crossref","is-referenced-by-count":15,"title":["Acute Acalculous Cholecystitis in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib"],"prefix":"10.3390","volume":"4","author":[{"given":"Leonardo","family":"Gomes da Fonseca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romualdo","family":"Barroso-Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Sabbaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Marcelo","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2014,4,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"ref2"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3816\/CGC.2009.n.011","article-title":"Acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib","volume":"7","author":"Gomez-Abuin","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1592\/phco.27.5.775","article-title":"Emphysematous cholecystitis in a patient with gastrointestinal stromal tumor treated with sunitinib","volume":"27","author":"de Lima","year":"2007","journal-title":"Pharmacotherapy"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/00004836-200302000-00015","article-title":"Clinical features of acute acalculous cholecystitis","volume":"36","author":"Ryu","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/ncpcardio1375","article-title":"Vascular complications of selected cancer therapies","volume":"5","author":"Daher","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CAD.0b013e3283403806","article-title":"Molecular basis of hypertension side effects induced by sunitinib","volume":"22","author":"Aparicio-Gallego","year":"2011","journal-title":"Anticancer Drugs"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"201529","DOI":"10.5402\/2011\/201529","article-title":"Acalculous cholecystitis in a patient with hepatocellular carcinoma on sorafenib","volume":"2011","author":"Sanda","year":"2011","journal-title":"ISRN Gastroenterol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4251\/wjgo.v4.i5.115","article-title":"A case of severe acalculous cholecystitis associated with sorafenib treatment for advanced hepatocellular carcinoma","volume":"4","author":"Aihara","year":"2012","journal-title":"World J Gastrointest Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/1471-2407-13-242","article-title":"The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors","volume":"13","author":"Rosen","year":"2013","journal-title":"BMC Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1053\/j.gastro.2005.12.034","article-title":"Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism","volume":"130","author":"Gaudio","year":"2006","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.beha.2009.01.001","article-title":"Thrombosis associated with angiogenesis inhibitors","volume":"22","author":"Elice","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinics and Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.clinicsandpractice.org\/index.php\/cp\/article\/viewFile\/635\/319","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mdpi.com\/2039-7283\/4\/1\/635\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T15:43:43Z","timestamp":1648914223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2039-7283\/4\/1\/635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,30]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,3]]}},"alternative-id":["cp.2014.635"],"URL":"https:\/\/doi.org\/10.4081\/cp.2014.635","relation":{},"ISSN":["2039-7283"],"issn-type":[{"value":"2039-7283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,30]]}}}